The FDA takes the position that a company’s truthful, nonmisleading statements about off-label use can constitute evidence of an intended use outside the label. Even while acknowledging that off-label use can be absolutely necessary for some maladies, and even while getting repeatedly clobbered by courts holding that truthful, nonmisleading communications about off-label use are protected by the First Amendment, the FDA stubbornly asserts the power to clamp down on such speech.
But the effective date of this misguided Final Rule has been postponed until March 19, 2018. In the meantime, interested parties may comment. In the first part of this article, we summarized PhRMA’s comments on the FDA’s proposed amendments to regulations regarding “intended uses.” PhRMA showed how the FDA’s insistence that it could read manufacturer’s minds about intended uses made no sense on an evidentiary basis and ran afoul of First Amendment considerations.
Today, we’ll tip our cyber caps to the Advanced Medical Technology Association (AdvaMed), which also issued well thought-out comments on the FDA’s proposal. To begin with, the AdvaMed letter excels at doing that thing that judges yell at dumb litigators for not doing in their motions — stating what relief is sought.
To continue reading, please visit law360.com